Pellegrini C, et al. - Researchers assessed 1-year outcome with a novel self-expanding transcatheter heart valve, the ACURATE neo (Symetis SA, a Boston Scientific Company, Ecublens, Switzerland) according to the updated Valve Academic Research Consortium (VARC-2). They examined 151 consecutive patients with severe aortic valve stenosis who were undergoing transfemoral transcatheter aortic valve replacement (TAVR) with the ACURATE neo. They mainly focused on the composite endpoints “clinical efficacy after 30 days” and “time-related valve safety.” The use of ACURATE neo was found to be associated with low all-cause mortality at 1 year and therefore carried a favorable safety profile. Furthermore, low rates of “clinical efficacy after 30 days” and “time-related valve safety” were shown by the reported VARC-2 defined composite endpoints at 1 year.